Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma
Phase 1
Completed
- Conditions
- Lymphoma, Marginal ZoneLymphoma, Mantle-CellLymphoma, FollicularLymphomaLymphoma, Large B-Cell, DiffuseLymphoma, B-CellLymphoma, Non-Hodgkin
- Interventions
- First Posted Date
- 2018-09-25
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- Triphase Research and Development III Corp.
- Target Recruit Count
- 32
- Registration Number
- NCT03682796
- Locations
- 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸Banner MD Anderson, Gilbert, Arizona, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath